简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
25
2024-07
Approval Obtained for Initiating Clinical Trial for the Novel ADC Candidate BA1302 in China
22
2024-07
Positive Profit Alert
16
2024-07
Acceptance of BLA in China for Aflibercept Intravitreous Injection (BA9101)
02
2024-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
04
2024-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
31
2024-05
Poll Results of the Annual General Meeting Held on 31 May 2024
27
2024-05
Acceptance of BLA in China for Dulaglutide Injection (BA5101)
27
2024-05
Denosumab Injection (Boluojia) for Oncology Indications Approved for Marketing by NMPA
06
2024-05
Monthly Return of Equity Issuer on Movements in Securities for The Month Ended 30 April 2024
29
2024-04
Form of Proxy for Use at Annual General Meeting to Be Held on 31 May 2024 (Applicable to Holders of H Shares)
2
3
4
5
6
Follow me
鲁公网安备37069102000284